- Home
- MBAV vs TSHA Comparison
MBAV vs TSHA Comparison
Compare MBAV & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBAV
- TSHA
- Stock Information
- Founded
- MBAV 2024
- TSHA 2019
- Country
- MBAV United States
- TSHA United States
- Employees
- MBAV N/A
- TSHA N/A
- Industry
- MBAV
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- MBAV
- TSHA Health Care
- Exchange
- MBAV NYSE
- TSHA Nasdaq
- Market Cap
- MBAV 359.4M
- TSHA 411.9M
- IPO Year
- MBAV 2024
- TSHA 2020
- Fundamental
- Price
- MBAV $10.00
- TSHA $2.01
- Analyst Decision
- MBAV
- TSHA Strong Buy
- Analyst Count
- MBAV 0
- TSHA 8
- Target Price
- MBAV N/A
- TSHA $6.38
- AVG Volume (30 Days)
- MBAV 41.9K
- TSHA 1.9M
- Earning Date
- MBAV 01-01-0001
- TSHA 11-12-2024
- Dividend Yield
- MBAV N/A
- TSHA N/A
- EPS Growth
- MBAV N/A
- TSHA N/A
- EPS
- MBAV N/A
- TSHA N/A
- Revenue
- MBAV N/A
- TSHA $12,873,000.00
- Revenue This Year
- MBAV N/A
- TSHA N/A
- Revenue Next Year
- MBAV N/A
- TSHA N/A
- P/E Ratio
- MBAV N/A
- TSHA N/A
- Revenue Growth
- MBAV N/A
- TSHA 34.05
- 52 Week Low
- MBAV $9.97
- TSHA $1.27
- 52 Week High
- MBAV $10.15
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- MBAV N/A
- TSHA 42.45
- Support Level
- MBAV N/A
- TSHA $1.99
- Resistance Level
- MBAV N/A
- TSHA $2.11
- Average True Range (ATR)
- MBAV 0.00
- TSHA 0.11
- MACD
- MBAV 0.00
- TSHA -0.01
- Stochastic Oscillator
- MBAV 0.00
- TSHA 9.84
About MBAV M3-BRIGADE ACQUISITION V CORP
M3-Brigade Acquisition V Corp is a blank check company.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.